Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other trials or therapies. This study includes a registry for longitudinal evaluation of patients whose cancer has FGFR mutations such as cholangiocarcinoma, pancreatic cancer, and others (telehealth).
Study Type
OBSERVATIONAL
Enrollment
1,000
Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
Ohio State University Wexner Medical Center
Columbus, Ohio, United States
RECRUITINGNumber of participants receiving new therapy based on study findings
Impact on clinical care
Time frame: Up to 24 Months
Average number of days to return results
Determine average number of days for return of results
Time frame: Up to 24 months
Ohio State University Comprehensive Cancer Center
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.